Clinical Trials

Title   University of Virginia & Merck (UVA-LACC-PD201)
Principal Investigator/ Physician   Jennifer Scalici, MD
Protocol┬áNo.   UVA-LACC-PD201
Open Date   07/12/2016
Cancer Site   Cervical
Status   Open
Contact Email   MCI Clinical Trials
Summary  

Protocol Title:  "A Randomized Phase Ii Study of Chemoradiation and Pembrolizumab for Locally Advanced Cervical Caner."

Inclusion Criteria: Histologically confirmed invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, stages IB2, IIA, IIB, IIIB and IVA, Stage IB1 with + pelvic or para0aortic nodes base on MRI also eligible; no evidence of distant metastases; recurrent cervical cancer is not eligible; ECOG performance status of 0-2.

Exclusion Criteria: Malignancy within the prior 5 years (exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy); diagnosis of immunodeficiency; know history of HIV, Hepatitis B/C, active TB, inflammatory bowel disease; hypersensitivity to pembrolizumab or any of its excipients; active autoimmune disease that has required systemic treatment in the past 2 years; known history or evidence of pneumonitis; known active CNS metastases and/or carcinomatous meningitis.

Clinical Trials.Gov Link:  https://clinicaltrials.gov/ct2/show/NCT02635360?term=UVA-LACC-PD201&rank=1

Email Newsletters

Connect With Us